Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  European Journal of Cancer

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0959-8049(03)00673-7PMID 14687787
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients

  2004cited by this paper
• Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells

  2004cited by this paper
• Prognostic value of intratumoral microvessel density, a measure of tumor angiogenesis, in node-negative breast carcinoma — results of a multiparametric study

  2004cited by this paper
• Ligand-induced, receptor-mediated dimerization and activation of EGF receptor.

  2002cited by this paper
• C-erbB receptors in squamous cell carcinomas of the head and neck: clinical significance and correlation with matrix metalloproteinases and vascular endothelial growth factors.

  2002cited by this paper
• Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels.

  2002cited by this paper
• Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor.

  2002cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer.

  2001cited by this paper
• The n e w e n g l a n d j o u r n a l of m e d i c i n e

  2001cited by this paper
• The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer.

  2001cited by this paper
• Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay.

  2001cited by this paper
• HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer.

  2001cited by this paper
• p53 and vascular‐endothelial‐growth‐factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma

  2000cited by this paper
• Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis

  2000cited by this paper
• Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.

  2000cited by this paper
• Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment.

  2000cited by this paper
• HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.

  1998cited by this paper
• erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.

  1998cited by this paper
• Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma.

  1998cited by this paper
• Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.

  1997cited by this paper
• ErbB2 assay in breast cancer: possibly improved clinical information using a quantitative method.

  1997cited by this paper
• The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erb B-2 in lymph node-negative breast cancer.

  1996cited by this paper
• [Significance of tumor angiogenesis as an independent prognostic factor in axillary node-negative breast cancer].

  1995cited by this paper
• 67‐kDa laminin‐receptor expression adds prognostic information to intra‐tumoral microvessel density in node‐negative breast cancer

  1995cited by this paper
• Gene therapy through signal transduction pathways and angiogenic growth factors as therapeutic targets in breast cancer

  1994cited by this paper
• Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer.

  1992cited by this paper
• Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

  1992cited by this paper
• Prognostic significance of her‐2/neu expression in breast cancer and its relationship to other prognostic factors

  1991cited by this paper

• A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)

  2024cites this paper
• A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)

  2024cites this paper
• Immunoexpression of HER2 pathway related markers in HER2 invasive breast carcinomas treated with trastuzumab.

  2023cites this paper
• Targeted doxorubicin delivery and release within breast cancer environment using PEGylated chitosan nanoparticles labeled with monoclonal antibodies.

  2021cites this paper
• Signaling pathways downstream to receptor tyrosine kinases: targets for cancer treatment

  2020cites this paper
• Overexpression of ERBB3 promotes proliferation, migration, and angiogenesis in nasopharyngeal carcinoma.

  2019cites this paper
• Novel Non–HER2-targeted Therapies in HER2+ Breast Cancer

  2019cites this paper
• HER-2/neu overexpression correlates with increased expression of VEGF in primary breast carcinoma

  2016cites this paper
• Biomarker triplet NAMPT/VEGF/HER2 as a de novo detection panel for the diagnosis and prognosis of human breast cancer.

  2016cites this paper
• Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.

  2015cites this paper
• Long-term remission of a Her2/neu positive primary breast cancer under double monoclonal antibody therapy with trastuzumab and bevacizumab

  2014cites this paper
• Antiangiogenic therapy: Patient selection and clinical outcomes

  2014cites this paper
• Angiogenic factors in relation to clinical effect in a phase II trial of weekly paclitaxel.

  2013cites this paper
• Prognostic role of human epidermal growth factor receptor 2 status in premenopausal early breast cancer treated with adjuvant tamoxifen.

  2013cites this paper
• Monoclonal Antibody-Based Targeted Therapy in Breast Cancer

  2012cites this paper
• Down-regulation of vascular endothelial growth factor expression by anti-her2/neu single chain antibodies

  2012cites this paper
• Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models

  2012cites this paper
• Development of drug conjugates for cancer therapy and evaluation of dual sirna silencing effect on breast cancer growth and invasion

  2012influential citation
• From DEPARTMENT OF ONCOLOGY AND PATHOLOGY Karolinska Institutet, Stockholm, Sweden PROGNOSTIC AND PREDICTIVE FACTORS IN VIETNAMESE BREAST CANCER: A COMPARISON WITH SWEDISH PATIENTS AND EFFECT ON SURVIVAL VU

  2012cites this paper
• Customization of tamoxifen therapy : not only a dream

  2011cites this paper
• Prädiktiver Wert und Verlaufsbeobachtung der Tumorvaskularisierung in der primär systemischen Therapie des Mammakarzinoms

  2011cites this paper
• Prolonged tamoxifen treatment increases relapse-free survival for patients with primary breast cancer expressing high levels of VEGF.

  2010cites this paper
• Inhibition of breast cancer cell growth and invasiveness by dual silencing of HER-2 and VEGF.

  2010cites this paper
• Bevacizumab for Advanced Breast Cancer

  2010cites this paper
• Antiangiogenic therapies in early-stage breast cancer.

  2010cites this paper
• The role of HER2 in cancer therapy and targeted drug delivery.

  2010cites this paper
• Bevacizumab in the treatment of patients with advanced breast cancer: where have we landed?

  2010cites this paper
• Targeted therapies in early-stage breast cancer: achievements and promises.

  2010cites this paper
• The Role of Neuregulin 1 β /ErbB signaling in the heart

  2009cites this paper
• Rôle du NGF dans l’angiogenèse du cancer du sein

  2009cites this paper
• Treatment of HER2-positive metastatic breast cancer following initial progression.

  2009cites this paper
• Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer.

  2009cites this paper
• Heregulin-Induced VEGF Expression via the ErbB3 Signaling Pathway in Colon Cancer

  2009cites this paper
• Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor

  2009cites this paper
• The role of Neuregulin-1beta/ErbB signaling in the heart.

  2009cites this paper
• An Autocrine VEGF / VEGFR 2 and p 38 Signaling Loop Confers Resistance to 4-Hydroxytamoxifen in MCF-7 Breast Cancer Cells

  2008cites this paper
• An Autocrine VEGF/VEGFR2 and p38 Signaling Loop Confers Resistance to 4-Hydroxytamoxifen in MCF-7 Breast Cancer Cells

  2008cites this paper
• The role of bevacizumab in breast cancer

  2008cites this paper
• Bevacizumab for advanced breast cancer.

  2007cites this paper
• VEGF signaling inhibitors: More pro-apoptotic than anti-angiogenic

  2007influential citation
• Increased incidence of lobular breast cancer in women treated with hormone replacement therapy: implications for diagnosis, surgical and medical treatment.

  2007cites this paper
• Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy

  2007cites this paper
• Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines

  2007cites this paper
• Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance.

  2006cites this paper
• Changes in the circulating plasma levels of VEGF and VEGF-D after adjuvant chemotherapy in patients with breast cancer and 1 to 3 positive lymph nodes.

  2006cites this paper
• Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions.

  2006cites this paper
• VEGF Expression is Associated with Negative Estrogen Receptor Status in Patients with Breast Cancer

  2006cites this paper
• Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose–dense sequential adjuvant chemotherapy

  2006influential citation
• Potential role of HER-2; in primary breast tumor with bone metastasis.

  2006cites this paper
• Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor.

  2005cites this paper
• Breast cancer biomarkers.

  2005cites this paper
• Association Between HER-2/neu and Vascular Endothelial Growth Factor Expression Predicts Clinical Outcome in Primary Breast Cancer Patients

  2005cites this paper
• Adjuvant chemotherapy for elderly patients (> or =70 years) with early high-risk breast cancer: a retrospective analysis of 260 patients.

  2005cites this paper
• [Non-functioning pituitary adenomas: clinical features and immunohistochemistry].

  2005cites this paper
• Caracterização clínica e imunoistoquímica dos adenomas clinicamente não-funcionantes de hipófise: clinical features and immunohistochemistry

  2005cites this paper
• VEGF-Targeting Therapy for Breast Cancer

  2005cites this paper
• Expression of basic fibroblastic growth factor (bFGF) in invasive ductal carcinoma of breast and its relation to angiogenesis and other prognostic parameters

  2005cites this paper